TA194: Bone loss (therapy-induced) in non-metastatic prostate cancer - denosumab (terminated appraisal)
This is a discussion on TA194: Bone loss (therapy-induced) in non-metastatic prostate cancer - denosumab (terminated appraisal) within the Updates from the Technology Assessment Authorities forum, part of the Industry News and Updates category; The summary for the published technology appraisal on Bone loss (therapy-induced) in non-metastatic prostate cancer - denosumab (terminated appraisal). ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
07-27-2010, 08:25 PM
|
|||
|
|||
TA194: Bone loss (therapy-induced) in non-metastatic prostate cancer - denosumab (terminated appraisal)
The summary for the published technology appraisal on Bone loss (therapy-induced) in non-metastatic prostate cancer - denosumab (terminated appraisal). It links to the published guidance and key documents.
More... 
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| TA147: Breast cancer (advanced & metastatic) - bevacizumab (terminated appraisal) | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| TA148: Lung cancer (non-small-cell) - bevacizumab (terminated appraisal) | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| TA150: Colorectal cancer (metastatic) - cetuximab (terminated appraisal) | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| TA175: Lung cancer (non-small-cell, second line) - gefitinib (terminated appraisal) | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| Anti-Osteoclast Monoclonal Antibody Prevents Bone Loss in Prostate Cancer | industry_news | Other Clinical Pharmacy News | 0 | 07-17-2008 01:52 PM |
© 2008 DrugManagementForum™ powered by |
 |